Edition:
India

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

2.15USD
22 Jun 2018
Change (% chg)

$-0.10 (-4.44%)
Prev Close
$2.25
Open
$2.30
Day's High
$2.30
Day's Low
$2.15
Volume
2,607,996
Avg. Vol
94,971
52-wk High
$22.10
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Versartis Q1 Loss Per Share $0.25
Wednesday, 9 May 2018 

May 8 (Reuters) - Versartis Inc ::VERSARTIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.25.CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018.  Full Article

Versartis reports Q3 loss $1.40/shr
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Versartis Inc :Versartis reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.40.Q3 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article

Versartis announces pricing of follow-on offering
Wednesday, 28 Sep 2016 

Versartis Inc : Announces pricing of follow-on offering .Pricing of an underwritten public offering of 4.9 million shares of its common stock at a public offering price of $12.25 per share.  Full Article

Versartis reports proposed offering of common stock
Wednesday, 28 Sep 2016 

Versartis Inc :Versartis announces proposed offering of common stock.  Full Article

Versartis presents data for Somavaratan
Saturday, 3 Sep 2016 

Versartis Inc : Versartis presents efficacy, safety, metabolic and adherence data for somavaratan in oral session at international congress of endocrinology . Somavaratan is currently being evaluated for treatment of pediatric ghd in pivotal phase 3 velocity trial in u.s., canada and europe . Data for pivotal phase 3 velocity trial anticipated in q3 2017, and j14vr5 phase 2/3 trial in japan .In adult ghd, top-line results from phase 2 vital trial in u.s., europe and australia are expected during second half of 2016..  Full Article

Versartis completes enrollment in phase 3 Velocity trial of Somavaratan in Pediatric GHD
Monday, 22 Aug 2016 

Versartis Inc :Announces completion of enrollment in phase 3 Velocity trial of Somavaratan in Pediatric GHD; line results are anticipated in q3 2017..  Full Article

Versartis says Q2 loss per share $0.75
Friday, 29 Jul 2016 

Versartis Inc : Versartis reports second quarter 2016 financial results . Q2 loss per share $0.75 .Q2 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Versartis Q1 Loss Per Share $0.25

* CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage: